Navigating the Generic vs. Brand-Name Divide
Welcome. If you’re a professional in the pharmaceutical and biotech space, you understand that the conversation about generic drugs goes […]
Navigating the Generic vs. Brand-Name Divide Read Post »
The Algorithmic Arbitrage: AI-Powered Branded Drug Portfolio Management in the Era of Unprecedented Risk and Opportunity
Introduction The branded pharmaceutical industry, long a bastion of high-margin innovation, stands at a precipice. It is caught in the
Mastering Drug Patent Prosecution Timing as a Strategic Weapon
Introduction: The 20-Year Illusion and the Race for Effective Patent Life In pharmaceutical innovation the 20-year patent term is both
Mastering Drug Patent Prosecution Timing as a Strategic Weapon Read Post »
Predict Pharma Price Moves Using Patent Data
The market value of a pharmaceutical company is the discounted sum of its future cash flows, and those cash flows
Predict Pharma Price Moves Using Patent Data Read Post »
Profit from the Patent Gap
Pharmaceteutical stock valuation is an exercise in probabilistic accounting. Traditional financial metrics fail because they are retrospective. A price-to-earnings (P/E)
Profit from the Patent Gap Read Post »
The Impact of Paragraph IV Filings on Mid-Cap Pharma Valuations: A Strategic Investor Guide
The pharmaceutical industry operates within a dual-track reality where the brilliance of molecular engineering is frequently secondary to the structural
Navigating Forfeiture: The 7 Ways Generic Companies Can Lose 180-Day Exclusivity
In pharmaceutical patent litigation, the 180-day generic drug exclusivity is the ultimate prize. It is the “brass ring” 1, a
Navigating Forfeiture: The 7 Ways Generic Companies Can Lose 180-Day Exclusivity Read Post »
The New GPS for Pharma Investment: Navigating the Data-Driven Decade
From Lagging Indicators to Leading Signals: The Strategic Imperative of Alternative Data For decades, investment decisions in the pharmaceutical and
The New GPS for Pharma Investment: Navigating the Data-Driven Decade Read Post »
Valuing a Drug Pipeline: How to Quantify the Strength of a Biotech’s Patent Portfolio
The Core Thesis: Patents as the Currency of Biopharma Value The Grand Paradox of Biotech Valuation The world of biotechnology
Valuing a Drug Pipeline: How to Quantify the Strength of a Biotech’s Patent Portfolio Read Post »
